Vaccinex Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Vaccinex stock.
View analyst ratings for Vaccinex or view top-rated stocks.

Wall Street analysts have given Vaccinex a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaccinex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Vaccinex saw a increase in short interest in May. As of May 28th, there was short interest totaling 357,000 shares, an increase of 37.2% from the May 13th total of 260,200 shares. Based on an average daily volume of 640,700 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.4% of the shares of the company are short sold.
View Vaccinex's Short Interest.

Vaccinex is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Vaccinex.

Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, May, 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.09.
View Vaccinex's earnings history.

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCNX shares have decreased by 36.0% and is now trading at $2.67.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued 12 month price targets for Vaccinex's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Vaccinex's stock price to reach $7.00 in the next year. This suggests a possible upside of 162.2% from the stock's current price.
View analysts' price targets for Vaccinex or view top-rated stocks among Wall Street analysts.

Some companies that are related to Vaccinex include Verrica Pharmaceuticals (VRCA), Kindred Biosciences (KIN), Spruce Biosciences (SPRB), Fulcrum Therapeutics (FULC), PDS Biotechnology (PDSB), Corbus Pharmaceuticals (CRBP), Theratechnologies (THERF), Kezar Life Sciences (KZR), BELLUS Health (BLU), Oncternal Therapeutics (ONCT), Jaguar Health (JAGX), Marker Therapeutics (MRKR), Kamada (KMDA), Seelos Therapeutics (SEEL) and Xeris Pharmaceuticals (XERS).
View all of VCNX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Vaccinex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.23%), Oppenheimer & Co. Inc. (0.15%), UBS Group AG (0.10%), Goldman Sachs Group Inc. (0.07%), Institute for Wealth Management LLC. (0.07%) and Virtu Financial LLC (0.07%). Company insiders that own Vaccinex stock include Albert Friedberg, Catalyst Group Managem General and Maurice Zauderer.
View institutional ownership trends for Vaccinex.

VCNX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and Oppenheimer & Co. Inc..
View insider buying and selling activity for Vaccinex or view top insider-selling stocks.

VCNX stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, UBS Group AG, Institute for Wealth Management LLC., Virtu Financial LLC, and Bank of New York Mellon Corp. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, Catalyst Group Managem General, and Maurice Zauderer.
View insider buying and selling activity for Vaccinex or or view top insider-buying stocks.

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCNX stock can currently be purchased for approximately $2.67.

Vaccinex has a market capitalization of $75.96 million and generates $630,000.00 in revenue each year.

Vaccinex employs 39 workers across the globe.

The official website for Vaccinex is www.vaccinex.com.

Vaccinex is headquartered at 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620.

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]